Morning Cancer Immunotherapy Timing Linked to Better Survival, Study Finds

The findings were shared by the BMJ, one of the UK’s leading medical journals, which noted that patients receiving the bulk of their immunotherapy sessions in the morning showed better overall survival outcomes. But the researchers behind the work were clear: the results are preliminary, and people should not draw firm conclusions yet.

Immunotherapy works by prompting the immune system to identify and attack cancer cells. It’s used across a range of cancer types and has become a standard part of treatment for many patients — including those cared for by NHS Kent and Medway services.

The caution from researchers matters here. Studies that find associations between timing and outcomes don’t automatically prove that one causes the other. There could be other factors at play — patients seen earlier in the day may differ from those seen later in ways that aren’t fully accounted for.

This isn’t the first time researchers have looked at how the body clock (known medically as the circadian rhythm) might affect how well cancer treatments work. The field, sometimes called chronotherapy, is an active area of research, but it hasn’t yet produced changes to standard NHS treatment scheduling.

For now, patients receiving immunotherapy on the NHS should continue to attend appointments as scheduled and raise any questions with their oncology team. Changes to treatment timing are a clinical decision, and nothing in these early findings suggests patients should seek to alter their own appointments.

Anyone with questions about cancer treatment can speak to their GP or call NHS 111. The cancer support charity Macmillan Cancer Support can also be reached on 0808 808 00 00, seven days a week.